Stem Cell Therapeutics Corp. Announces The Date For The Release Of Top-Line Results In The Modified REGENESIS Phase IIb Stroke Trial
August 04, 2017
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) announced today that the Company will be instructing its third party contract researchers to finalize the patient data base for the primary endpoint data of the modified REGENESIS- Phase IIb stroke trial after the markets have closed on Friday May 21. At this time the blinded data base and the key to unlock it are held by two different independent contractors. The modified REGENESIS- Phase IIb trial, a placebo controlled, double blinded, 3:1 randomized clinical study, enrolled 96 patients with acute ischemic stroke between August 2009 and January 24, 2010. Once the top-line primary endpoint data is unlocked a preliminary analysis of this data can be conducted by the Company for this key Phase IIb clinical trial of NTx®-265 in acute stroke. Top line results for primary endpoint data are expected to be announced prior to markets opening on May 25th, 2010.
SCT management is unaware of any information on the Company that would have caused the dramatic drop in SCT's stock price earlier today.
Dr. Alan Moore, President & CEO of SCT commented as follows:
"The modified REGENESIS- Phase IIb stroke trial has entered into the final stages of data analysis and the reporting of top-line results. With the solid efforts of our team we are anticipating the release of top-line primary endpoint results for the Phase IIb clinical trial on May 25th, 2010. The change in our stock price today was very unexpected and since the data has not been unblinded, we are unaware of any information that would have impacted our stock price in such a manner."
Source
Stem Cell Therapeutics Corp.